As weight loss medications containing active ingredients like semaglutide continue to define a new chapter in metabolic ...

Largest cellular study of gut tissue unveils the genes and pathways driving inflammatory bowel disease, suggesting new therapeutic targets.

Scientists have created the most detailed cell map to date showing how genetic variation influences inflammatory bowel disease (IBD), revealing the specific cells and genes that drive the disease.

Nipocalimab - the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus - is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated ...